Neuroscience 2001 Abstract
| Presentation Number: | 702.2 |
|---|---|
| Abstract Title: | A NOVEL AMPA RECEPTOR ANTAGONIST, ER-099487, AMELIORATES DISEASE SYMPTOMS OF EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS. |
| Authors: |
Hanada, T.*1
; Ohgoh, M.1
; Ueno, M.1
; Hatakeyama, S.1
; Smith, T.2
; Nishizawa, Y.1
1Tsukuba Research Laboratories, Eisai Co., Ltd., Tsukuba-shi, Japan 2Eisai London Research Laboratories Ltd., London, United Kingdom |
| Primary Theme and Topics |
Synaptic Transmission and Excitability - Ligand Gated Ion Channels -- Glutamate receptors: Non-NMDA receptors |
| Session: |
702. Ligand gated ion channels: glutamate receptors: non-NMDA receptors--AMPA and kinate receptors in disease and excitotoxicity Poster |
| Presentation Time: | Wednesday, November 14, 2001 9:00 AM-10:00 AM |
| Location: | Exhibit Hall C-56 |
| Keywords: | EXCITATORY AMINO ACID, DEMYELINATION |
AMPA type glutamate receptors have major roles in excitatory fast synaptic transmission in CNS and the excessive activation of the receptors is implicated in the pathogenesis of various neurodegenerative diseases. Recent studies have indicated that antagonism at AMPA receptors affects the disease process of experimental autoimmune encepharomylelitis (EAE) (Nature Med. (2000) 6, 62; Ohgoh et al., SFN 2001 abstract). Thus orally active antagonists of the AMPA type glutamate receptors might be useful for the treatment of multiple sclerosis. ER-099487 is a highly selective AMPA type glutamate receptor antagonist as shown by in vitro and in vivo assays (Ueno et al. SFN 2001 abstract). To examine the effect of ER-099487 in EAE, disease ameliorative effect of ER-099487 was evaluated in an acute Lewis rat EAE model. ER-099487 was administered orally between 7 and 16 days post immunization (dpi). This treatment dose-dependently reduced disease severity and delayed the onset of the disease. The treatment of animals for shorter period (7 and 8 days dpi) caused the delay of disease onset without reduction in disease severity, while treatment (10 to 12 dpi) reduced only disease severity. These results suggest that there are two disease phases that include alteration in AMPA receptor activity during the course of EAE.
Sample Citation:
[Authors]. [Abstract Title]. Program No. XXX.XX. 2001 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2001. Online.
Copyright © 2001-2026 Society for Neuroscience; all rights reserved. Permission to republish any abstract or part of any abstract in any form must be obtained in writing by SfN office prior to publication.
